CCOP Goals and Objectives (2009-2014) The overall goal of MeritCare Hospital CCOP is to provide state-of-the-art cancer care to patients and families, as close to home as possible, through participation in National Cancer Institute (NCI) approved clinical trials. Program Objectives: 1) Increase the number of eligible patients place on NCI approved cancer treatment clinical research trials. 2) Facilitate wider community participation, including minorities, women, and other underserved populations in cancer treatment, prevention, and control research approved by NCI. 3) Continue to enhance the participation of primary healthcare providers and other specialist with the CCOP investigators in cancer treatment and control research. 4) Increase the quality and efficiency of data management systems/processes. 5) Expand participation in NCI approved cancer prevention and control clinical research trials.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-SRRB-Y (J1))
Program Officer
Kelaghan, Joseph
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Sanford Clinic
United States
Zip Code
Sio, Terence T; Atherton, Pamela J; Birckhead, Brandon J et al. (2016) Repeated measures analyses of dermatitis symptom evolution in breast cancer patients receiving radiotherapy in a phase 3 randomized trial of mometasone furoate vs placebo (N06C4 [alliance]). Support Care Cancer 24:3847-55
Neal, Joel W; Dahlberg, Suzanne E; Wakelee, Heather A et al. (2016) Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial. Lancet Oncol 17:1661-1671
Park, Haeseong; Qin, Rui; Smith, Thomas J et al. (2015) North Central Cancer Treatment Group N10C2 (Alliance): a double-blind placebo-controlled study of magnesium supplements to reduce menopausal hot flashes. Menopause 22:627-32
Barton, Debra L; Thanarajasingam, Gita; Sloan, Jeff A et al. (2014) Phase III double-blind, placebo-controlled study of gabapentin for the prevention of delayed chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy, NCCTG N08C3 (Alliance). Cancer 120:3575-83
Dronca, Roxana S; Allred, Jacob B; Perez, Domingo G et al. (2014) Phase II study of temozolomide (TMZ) and everolimus (RAD001) therapy for metastatic melanoma: a North Central Cancer Treatment Group study, N0675. Am J Clin Oncol 37:369-76
Province, M A; Goetz, M P; Brauch, H et al. (2014) CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations. Clin Pharmacol Ther 95:216-27
Kottschade, Lisa A; Suman, Vera J; Perez, Domingo G et al. (2013) A randomized phase 2 study of temozolomide and bevacizumab or nab-paclitaxel, carboplatin, and bevacizumab in patients with unresectable stage IV melanoma : a North Central Cancer Treatment Group study, N0775. Cancer 119:586-92
Brown, Lindsay C; Atherton, Pamela J; Neben-Wittich, Michelle A et al. (2013) Assessment of long-term rectal function in patients who received pelvic radiotherapy: a pooled North Central Cancer Treatment Group trial analysis, N09C1. Support Care Cancer 21:2869-77
Galanis, Evanthia; Anderson, S Keith; Lafky, Jackie M et al. (2013) Phase II study of bevacizumab in combination with sorafenib in recurrent glioblastoma (N0776): a north central cancer treatment group trial. Clin Cancer Res 19:4816-23
Barton, Debra L; Burger, Kelli; Novotny, Paul J et al. (2013) The use of Ginkgo biloba for the prevention of chemotherapy-related cognitive dysfunction in women receiving adjuvant treatment for breast cancer, N00C9. Support Care Cancer 21:1185-92

Showing the most recent 10 out of 134 publications